Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "Fangsheng Jianmeng"), has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its chemical generic drug research project, Relugolix tablets, which is a GnRH receptor antagonist used for the treatment of advanced prostate cancer [1]. Group 1 - Fangsheng Jianmeng has obtained regulatory approval for the clinical trial of Relugolix tablets [1]. - Relugolix is indicated for the treatment of adult patients with advanced prostate cancer [1].